Identifying clinical response to daratumumab therapy in relapsed/refractory multiple myeloma using a patient-derived in vitro model.
Niels van NieuwenhuijzenMarta CuencaLeonie AbbinkMargot JakVictor PeperzakMonique C MinnemaPublished in: EJHaem (2023)
Response to daratumumab in patients with relapsed/refractory multiple myeloma is heterogeneous, and a reliable biomarker of response is lacking. We aimed to develop a method that identifies response to daratumumab therapy. Patient-derived MM cells were collected before start of daratumumab treatment and were cultured in a hydrogel-based culture system. The extent of antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro was associated with both clinical response and progression-free survival in corresponding patients. Together, our results demonstrate that in vitro sensitivity to daratumumab therapy in a hydrogel culture with primary MM cells might be used to identify patients most likely to benefit from treatment.
Keyphrases
- multiple myeloma
- end stage renal disease
- induced apoptosis
- ejection fraction
- chronic kidney disease
- newly diagnosed
- free survival
- drug delivery
- acute lymphoblastic leukemia
- cell cycle arrest
- gene expression
- oxidative stress
- genome wide
- cell death
- patient reported
- hodgkin lymphoma
- combination therapy
- mesenchymal stem cells
- pi k akt
- wound healing